Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Botanical

or Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)

Use the filters below to narrow your results.

None (1) · 7-Hydroxymitragynine (1) · Acacia confusa (1) · Amanita muscaria (1) · Ayahuasca (1) · Blue lotus (1) · Butorphanol (1) · Calea zacatechichi (1) · Codeine (2) · Datura (1) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ethylmorphine (1) · Fentanyl (1) · Harmaline (1) · Harmine (1) · Hawaiian Baby Woodrose (1) · Hydrocodone (1) · Hydromorphone (1) · Iboga (1) · Kava (1) · Kratom (1) · Levorphanol (1) · Meperidine (1) · Mitragynine (1) · Morning Glory (1) · Myristicin (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Peyote (1) · Psilocybin mushrooms (1) · Salvia divinorum (1) · San Pedro cactus (1) · Syrian rue (1) · Tapentadol (1) · Tetrahydroharmine (1) · Yopo (1)

None (28) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Nuplazid (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Apomorphine and nuciferine; dopaminergic activity (1) · Contains atropine, scopolamine, hyoscyamine (1) · Contains bufotenin and DMT (1) · Contains harmine, harmaline, tetrahydroharmine (1) · Contains ibogaine; kappa-opioid agonist (1) · Contains LSA (2) · Contains mescaline (2) · Contains muscimol and ibotenic acid (1) · Contains psilocybin and psilocin (1) · Contains salvinorin A (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · DMT-containing plant used in psychedelic preparations (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Mechanism incompletely understood (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial MAOI; anticholinergic effects (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (4) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible MAO-A inhibitor; beta-carboline (1) · Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Weak serotonin reuptake inhibitor; beta-carboline (1)

None (38) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (38) · 34 mg PO once daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (38) · 10 mg, 34 mg capsules/tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (38) · 34 mg/d (1) · 360 mg/day (1)

None (38) · Oral (1) · PO (only formulation marketed in the US). (1)

None (38) · 30–60 min (PO) (1) · Benefit over weeks of dosing (1)

None (38) · 4–6 hours (1) · Daily dosing (1)

None (38) · 2.5–3 hours (1) · ~57 hours (parent), ~200 h (active metabolite) (1)

None (38) · Not characterized; oral dosing once daily (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (38) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data; avoid (1)

None (38) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)